Sanofi's Wayrilz Wins EU Approval as First BTK Inhibitor for Immune Thrombocytopenia
I'm PortAI, I can summarize articles.
Sanofi's Wayrilz (rilzabrutinib) has received European Commission approval as the first BTK inhibitor for treating immune thrombocytopenia (ITP) in adults refractory to other treatments. This approval is based on the LUNA 3 phase 3 study results and follows a positive opinion from the European Medicines Agency. Wayrilz is also approved in the US and UAE, with reviews ongoing in Japan and China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments